SIC
NRIX icon

SJS Investment Consulting’s Nurix Therapeutics NRIX Stock Holding History

SJS Investment Consulting’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23K Buy
+92
New +$1.57K ﹤0.01% 1733
2026
Q1 		– Sell
-50
Closed -$949 – 2543
2025
Q4 		$949 Hold
50
– – ﹤0.01% 1321
2025
Q3 		$462 Hold
50
– – ﹤0.01% 1259
2025
Q2 		$570 Hold
50
– – ﹤0.01% 1071
2025
Q1 		$594 Buy
+50
New +$836 ﹤0.01% 1188

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SJS Investment Consulting's NRIX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 92 shares worth $2.23K. The stake represents ﹤0.01% of the portfolio and ranks #1733 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in NRIX as recently as Q4 2025.

SJS Investment Consulting first reported a position in NRIX in Q1 2025 and has held it in 5 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • SJS Investment Consulting held 92 shares of Nurix Therapeutics worth $2.23K as of Q2 2026.
  • Nurix Therapeutics was a new SJS Investment Consulting position in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1733 holding.
  • SJS Investment Consulting first reported a position in Nurix Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.